The spinal orthopedics business, long focused on traditional fixation tools such as screws, dowels, cements, and more recently, interbody fusion cages, has been undergoing a slow evolution that also incorporates a biological approach to bone healing. Orthovita believes its glass/resin-based bioactive materials mimic the biology of bone healing better than previous synthetics, and that these materials can more easily incorporate biologic agents for an added bone-healing boost. Now the company faces the challenge of generating the data that will differentiate it from a host of competitors making similar claims and enable it to penetrate a market inherently slow to adopt new technology.
by Mark L. Ratner
The spinal orthopedics business, long focused on traditional fixation tools such as screws, dowels, cements, and more recently, interbody fusion...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.
Facing rising costs and tighter regulations, PBMs and insurers are accelerating the shift to value-based drug coverage, demanding stronger proof of therapeutic and economic benefit from pharma.
Akelos is developing a first-in-class, non-addictive HCN1 inhibitor for peripheral neuropathic pain, based on anesthesiology research from Weill Cornell. The compound is designed to avoid the brain and heart, and has shown strong preclinical efficacy and safety with NIH backed development underway.
